Pooled Analysis Supports Bioequivalence Between MB02 and Ref

In a new pooled analysis of 3 pharmacokinetic studies, the investigators confirmed the bioequivalence, safety, and immunogenicity between biosimilar MB02 and European Union approved bevacizumab and US-approved bevacizumab.

Related Keywords

Spain , Japan , Madrid , United States , Japanese , , Mabxience Research , European Union , New England Journal , Body Mass Index , Medical Department , European Union Approved , Biosimilar , Biosimilars , Mb02 , Bevacizumab , Bioequivalence , Cancer Treatment , Pooled Analysis ,